---
title: "Akkermansia muciniphila — Evidence & Citations | Magellan"
description: "Natural sources, dosing and cited research for Akkermansia muciniphila. Akkermansia muciniphila is a mucin-degrading, Gram-negative anaerobic bacterium…"
url: "https://magellanlongevity.com/m/akkermansia.md"
canonical: "https://magellanlongevity.com/m/akkermansia.html"
html: "https://magellanlongevity.com/m/akkermansia.html"
type: "molecule"
slug: "akkermansia"
evidence_grade: "Emerging evidence"
evidence_tier: "emerging"
citations: 14
updated: 2026-08-11
author: "Gabriel Radu, DO"
author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765."
publisher: "Magellan Longevity"
content_format: "markdown"
---

# Akkermansia muciniphila

[Home](https://magellanlongevity.com/) › Molecules › Akkermansia muciniphila

**HTML version:** https://magellanlongevity.com/m/akkermansia.html · **In the Magellan app:** https://magellanlongevity.com/#/search/Akkermansia%20muciniphila

## What it is

Akkermansia muciniphila is a mucin-degrading, Gram-negative anaerobic bacterium that resides in the intestinal mucus layer and typically represents roughly 1-5% of the human gut microbiota. Its relative abundance is often reduced in people with obesity, type 2 diabetes, hypertension and other metabolic disorders. It is regarded as a 'next-generation' beneficial microbe or postbiotic: a specific outer-membrane protein, Amuc\_1100, signals through Toll-like receptor 2, and notably a pasteurized (non-living) form has retained or even enhanced its metabolic effects in preclinical models.

## What the human evidence shows

In a randomized, double-blind proof-of-concept trial in overweight or obese insulin-resistant adults, three months of daily supplementation with A. muciniphila (particularly the pasteurized form, at 10^10 cells/day) was safe and improved insulin sensitivity (+28.6%), insulinemia (-34%) and total cholesterol (-8.7%) while lowering markers of liver dysfunction and inflammation. Follow-up trials have since reported weight-loss maintenance in people with overweight and obesity and improved muscle strength with a pasteurized strain, but results are mixed: a 2025 trial in type 2 diabetes found benefits only in participants whose baseline gut Akkermansia was low, and a larger 2026 multicenter trial in metabolic syndrome missed its primary insulin-sensitivity endpoint overall, with benefits confined to prediabetic, older (63+) and low-baseline subgroups. Mechanistically the bacterium thickens the gut mucus layer, strengthens the intestinal barrier and modulates host immunity. The human trial base remains small—a handful of mostly short trials, several from the same research lineage—with no long-term safety or hard-outcome data, and responses may depend on a person's baseline Akkermansia levels. This evidence describes the microorganism Akkermansia muciniphila and its mechanisms in general, not this specific commercial product.

## Evidence grade: Emerging evidence

- **Dose used in studies:** The key trial (Depommier 2019) gave 10^10 (10 billion) cells/day of pasteurized A. muciniphila for 3 months, improving insulin sensitivity and cholesterol in overweight adults.
- **Dose from food:** Not obtainable from food: Akkermansia is a native gut microbe, not present in any food or normal probiotic; diet can only feed existing colonies via fiber and polyphenols (chicory inulin, cranberry, grapes).
- **Caveat:** A flagship pilot RCT and 2025-2026 follow-up trials show real but modest benefits on insulin sensitivity, weight and HbA1c, but the trial base is small, a 2026 multicenter trial missed its primary endpoint, and benefits may appear mainly in people with low baseline Akkermansia. No long-term safety or hard-outcome data yet.

## Where it comes from without a bottle

Food, exercise and behaviour routes to the same pathway, each with its citation.

| Natural source | How it works | Citation |
| --- | --- | --- |
| Prebiotic fiber & polyphenol foods (onion, garlic, oats, berries) | Akkermansia is fed, not swallowed: a meta-analysis of six human studies found inulin, galacto-oligosaccharides and polyphenols stimulate it, so fiber- and polyphenol-rich plants feed it for you. | Food Funct 2024 [PMID 38590256](https://pubmed.ncbi.nlm.nih.gov/38590256/) |
| Cranberries (and other polyphenol-rich berries) | Cranberry fibers and polyphenols act as a prebiotic; whole-cranberry powder raised Akkermansia and health-related short-chain fatty acids in a human gut model. | BioTech (Basel) 2022 [PMID 35822787](https://pubmed.ncbi.nlm.nih.gov/35822787/) |
| Polyphenol-rich diet (green tea, grapes, cocoa) | High-polyphenol foods shift the gut ecosystem in your favor; a systematic review found polyphenol intake enriches Akkermansia muciniphila alongside lactic-acid bacteria. | Complement Ther Med 2018 [PMID 30670241](https://pubmed.ncbi.nlm.nih.gov/30670241/) |

### What those papers actually say

1. **Prebiotic fiber & polyphenol foods (onion, garlic, oats, berries)**
   Food Funct 2024 · [PMID 38590256](https://pubmed.ncbi.nlm.nih.gov/38590256/) · [DOI 10.1039/d4fo00428k](https://doi.org/10.1039/d4fo00428k)

   > metabolic pathways associated with carbohydrate metabolism and short-chain fatty acid release were enriched following the GOS intervention

2. **Cranberries (and other polyphenol-rich berries)**
   BioTech (Basel) 2022 · [PMID 35822787](https://pubmed.ncbi.nlm.nih.gov/35822787/) · [DOI 10.3390/biotech11020014](https://doi.org/10.3390/biotech11020014)

   > FCP significantly increased levels of health-related short-chain fatty acids (SCFA: acetate, propionate and butyrate)

3. **Polyphenol-rich diet (green tea, grapes, cocoa)**
   Complement Ther Med 2018 · [PMID 30670241](https://pubmed.ncbi.nlm.nih.gov/30670241/) · [DOI 10.1016/j.ctim.2018.11.019](https://doi.org/10.1016/j.ctim.2018.11.019)

   > the growth of Lactic acid bacteria and Akkermansia muciniphila is enriched

## Products built on Akkermansia muciniphila

| Product | Evidence grade | Typical price |
| --- | --- | --- |
| [Akkermansia muciniphila Probiotic](https://magellanlongevity.com/p/200.md) | Emerging evidence | $64.00 |

## The research

### Cited studies

1. **Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study**
   Nature Medicine 2019 · [PMID 31263284](https://pubmed.ncbi.nlm.nih.gov/31263284/) · [DOI 10.1038/s41591-019-0495-2](https://doi.org/10.1038/s41591-019-0495-2)

   > Akkermansia muciniphila supplementation was safe and well tolerated and improved insulin sensitivity and markers of metabolic health in overweight, insulin-resistant adults.

2. **Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels.**
   Gut Microbes 2026 · [PMID 42343233](https://pubmed.ncbi.nlm.nih.gov/42343233/) · [DOI 10.1080/19490976.2026.2690689](https://doi.org/10.1080/19490976.2026.2690689)

   > The primary endpoint of whole-body insulin sensitivity (Matsuda index) did not differ after 4-months of daily administration of capsules containing 30 billion cells of pasteurizedMucT compared to placebo in the intention-to-treat subjects.

3. **A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice.**
   Nat Med 2016 · [PMID 27892954](https://pubmed.ncbi.nlm.nih.gov/27892954/) · [DOI 10.1038/nm.4236](https://doi.org/10.1038/nm.4236)

   > We demonstrated that Amuc_1100, a specific protein isolated from the outer membrane of A. muciniphila, interacts with Toll-like receptor 2, is stable at temperatures used for pasteurization, improves the gut barrier and partly recapitulates the beneficial effects of the bacterium.

4. **Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology.**
   Gut 2015 · [PMID 26100928](https://pubmed.ncbi.nlm.nih.gov/26100928/) · [DOI 10.1136/gutjnl-2014-308778](https://doi.org/10.1136/gutjnl-2014-308778)

   > A. muciniphila is associated with a healthier metabolic status and better clinical outcomes after CR in overweight/obese adults.

5. **Akkermansia muciniphila, a New Generation of Beneficial Microbiota in Modulating Obesity: A Systematic Review.**
   Microorganisms 2021 · [PMID 34065217](https://pubmed.ncbi.nlm.nih.gov/34065217/) · [DOI 10.3390/microorganisms9051098](https://doi.org/10.3390/microorganisms9051098)

   > Although there are studies that support the protective effect of this strategy, the effects on the prevention of obesity on humans are not clear yet and need more investigation.

6. **Probiotics, Prebiotics, Synbiotics, Postbiotics, and Obesity: Current Evidence, Controversies, and Perspectives.**
   Curr Obes Rep 2020 · [PMID 32472285](https://pubmed.ncbi.nlm.nih.gov/32472285/) · [DOI 10.1007/s13679-020-00379-w](https://doi.org/10.1007/s13679-020-00379-w)

   > Bifidobacterium and Lactobacillus strains are still the most widely used probiotics in functional foods and dietary supplements, but next generation probiotics, such as Faecalibacterium prausnitzii, Akkermansia muciniphila, or Clostridia strains, have demonstrated promising results.

7. **Action and function of Akkermansia muciniphila in microbiome ecology, health and disease.**
   Best Pract Res Clin Gastroenterol 2017 · [PMID 29566906](https://pubmed.ncbi.nlm.nih.gov/29566906/) · [DOI 10.1016/j.bpg.2017.10.001](https://doi.org/10.1016/j.bpg.2017.10.001)

   > A. muciniphila is particularly effective in increasing mucus thickness and increasing gut barrier function.

8. **Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms.**
   Nat Rev Gastroenterol Hepatol 2022 · [PMID 35641786](https://pubmed.ncbi.nlm.nih.gov/35641786/) · [DOI 10.1038/s41575-022-00631-9](https://doi.org/10.1038/s41575-022-00631-9)

   > The causal evidence derived from a variety of animal models performed in different laboratories and recently was also recapitulated in a human proof-of-concept trial.

9. **Akkermansia muciniphila: a promising target for the therapy of metabolic syndrome and related diseases.**
   Chin J Nat Med 2019 · [PMID 31831130](https://pubmed.ncbi.nlm.nih.gov/31831130/) · [DOI 10.1016/S1875-5364(19)30101-3](https://doi.org/10.1016/S1875-5364%2819%2930101-3)

   > Its specialization in mucin degradation makes it a key microorganism that maintains intestinal mucosal barrier function.

10. **Extracellular Vesicles from Child Gut Microbiota Enter into Bone to Preserve Bone Mass and Strength.**
    Adv Sci (Weinh) 2021 · [PMID 33977075](https://pubmed.ncbi.nlm.nih.gov/33977075/) · [DOI 10.1002/advs.202004831](https://doi.org/10.1002/advs.202004831)

    > colonization with GM from children (CGM) but not from the elderly (EGM) prevents decreases in bone mass and bone strength in conventionally raised, ovariectomy (OVX)-induced osteoporotic mice.

11. **Akkermansia muciniphila Protects Against Antibiotic-Associated Diarrhea in Mice.**
    Probiotics Antimicrob Proteins 2023 · [PMID 37314693](https://pubmed.ncbi.nlm.nih.gov/37314693/) · [DOI 10.1007/s12602-023-10101-6](https://doi.org/10.1007/s12602-023-10101-6)

    > Pasteurized Akk or Amuc_1100 significantly decreased the diarrhea status score and colon injury of AAD model mice.

12. **Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut.**
    Cell metabolism 2025 · [PMID 39879980](https://pubmed.ncbi.nlm.nih.gov/39879980/)

    > 12-week RCT in overweight/obese type 2 diabetes (n=58): no overall between-group benefit, but significant weight, fat-mass and HbA1c reductions in participants with low baseline gut Akkermansia.

13. **Pasteurized Akkermansia muciniphila Muc(T) for weight loss maintenance in people with overweight and obesity: a controlled randomized trial.**
    Nature medicine 2026 · [PMID 42120725](https://pubmed.ncbi.nlm.nih.gov/42120725/)

    > Randomized controlled trial: pasteurized A. muciniphila MucT supported weight-loss maintenance in people with overweight and obesity.

14. **Pasteurized Akkermansia muciniphila HB05 (HB05P) Improves Muscle Strength and Function: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.**
    Nutrients 2024 · [PMID 39683431](https://pubmed.ncbi.nlm.nih.gov/39683431/)

    > 12-week RCT: pasteurized A. muciniphila strain HB05 improved muscle strength and function versus placebo.

## Structured data

```json
{"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/m/akkermansia.html#page","url":"https://magellanlongevity.com/m/akkermansia.html","name":"Akkermansia muciniphila","description":"Natural sources, dosing and cited research for Akkermansia muciniphila","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/m/akkermansia.md"},"dateModified":"2026-08-11"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Akkermansia muciniphila","item":"https://magellanlongevity.com/m/akkermansia.html"}]},{"@type":"ItemList","@id":"https://magellanlongevity.com/m/akkermansia.html#items","numberOfItems":1,"itemListElement":[{"@type":"ListItem","position":1,"name":"Akkermansia muciniphila Probiotic","url":"https://magellanlongevity.com/p/200.html"}]}]}
```

## Related on Magellan Longevity

- [Akkermansia muciniphila Probiotic](https://magellanlongevity.com/p/200.md)
- [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md)
- [Longevity research map](https://magellanlongevity.com/longevity-research-map.html)
- [Pathway universe](https://magellanlongevity.com/pathway-universe.html)

## Scope and disclosures

Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication.

Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases.

Reviewed for accuracy by a board-certified physician (DO).